Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer

Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer

Melatonin has numerous anti-cancer properties reported to influence cancer initiation, promotion, and metastasis. With the need for effective hormone therapies (HT) to treat menopausal symptoms without increasing breast cancer risk, co-administration of nocturnal melatonin with a natural, low-dose H...

Full description

Bibliographic Details
Main Authors: Balasunder R. Dodda, Corry D. Bondi, Mahmud Hasan, William P. Clafshenkel, Katie M. Gallagher, Mary P. Kotlarczyk, Shalini Sethi, Ethan Buszko, Jean J. Latimer, J. Mark Cline, Paula A. Witt-Enderby, Vicki L. Davis
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Oncology
Subjects:
breast cancer
estradiol
HER2/Neu
melatonin
menopausal hormone therapy
metastasis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00525/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00525/full

Similar Items